Health Affairs August 18, 2020
Anand Shah, Kushal T. Kadakia, Peter Marks, Patrizia Cavazzoni, Stephen Hahn

More than 750,000 deaths have occurred worldwide as a result of the novel coronavirus as of August 2020. Clinicians have reported a range of physiological abnormalities in severely ill COVID-19 patients, including respiratory distresssevere immune reactions, and cardiac and vascular complications. Research also suggests that death rates are alarmingly high for patients requiring ventilator support, demonstrating the need for therapeutic interventions that can prevent the escalation of disease severity.

The Food and Drug Administration (FDA) has taken a number of steps to accelerate the development of COVID-19 therapeutics, from issuing guidance documents for product developers, to creating initatives to facilitate regulatory review. We also continue to engage in public-private partnerships that prioritize evaluating potential therapeutics and vaccines in clinical trials and leveraging real-world data to better understand...

Today's Sponsors

ZeOmega
holon
ClearDATA

Today's Sponsors

Augmedix
ZeOmega

Today's Sponsor

Augmedix

2020-08-18T18:16:01-04:00